LTGO.US Latigo Biotherapeutics, Inc. Common Stock
- Market cap
- USD 869M
- P/E
- -
- P/B
- 2.22x
- ROE
- -23.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LTGO.US undervalued?
Graham numberThe Graham number of Latigo Biotherapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Latigo Biotherapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Latigo Biotherapeutics, Inc. Common Stock yet.
Latigo Biotherapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment…
Full company profileLatigo Biotherapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Latigo Biotherapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | -63.5M | -110M | -96.2M |
| EBITDA | -63.2M | -110M | -92.1M |
| Net Income | -61.2M | -109M | -92.9M |
| EPS | -1.02 | -2.48 | -2.46 |
| Balance Sheet | |||
| Total Assets | 22.9M | 75.5M | 408M |
| Total Liabilities | 152M | 307M | 14.5M |
| Shareholders' Equity | -130M | -232M | 394M |
| Cash & Short-term Investments | 17.9M | 69.4M | 401M |
| Total Debt | - | 690K | 1.19M |
| Cash Flow | |||
| Operating Cash Flow | -51.0M | -97.6M | -90.5M |
| Capital Expenditure | 72.0K | 136K | 195K |
| Free Cash Flow | -51.0M | -97.7M | -90.7M |
| Ratios | |||
| ROE | - | - | -23.6% |
| ROA | -267.6% | -144.6% | -22.8% |
| Debt to Equity | - | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Latigo Biotherapeutics, Inc. Common Stock dividends
Latigo Biotherapeutics, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Latigo Biotherapeutics, Inc. Common Stock
- Insiders 6.42%
- Institutions 90.29%
- Public & others 3.28%
- Shares outstanding 66.3M
- Free float 10.4M
Top funds holding LTGO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Contrafund | 868K | 1.31% | -7.67% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 629K | 0.95% | +1,037.18% | Sep 2026 |
| abrdn Healthcare Investors | 586K | 0.88% | +130.87% | Oct 2026 |
| Fidelity Select Biotechnology | 480K | 0.72% | 0.00% | Aug 2026 |
| abrdn Life Sciences Investors | 280K | 0.42% | +44.63% | Oct 2026 |
| Fidelity Select Health Care | 213K | 0.32% | 0.00% | Aug 2026 |
| abrdn Healthcare Opportunities | 210K | 0.32% | +7.23% | Sep 2026 |
| T. Rowe Price New Horizons | 209K | 0.32% | -0.99% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 191K | 0.29% | 0.00% | Sep 2026 |
| Fidelity Contrafund K6 | 184K | 0.28% | -7.62% | Sep 2026 |
| abrdn World Healthcare | 135K | 0.20% | +7.28% | Sep 2026 |
| Fidelity Advisor Health Care I | 105K | 0.16% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 98.9K | 0.15% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 88.7K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Small Cap Discovery | 69.6K | 0.11% | 0.00% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 65.0K | 0.10% | -17.23% | Sep 2026 |
| Fidelity Series Small Cap Discovery | 60.0K | 0.09% | 0.00% | Aug 2026 |
| Fidelity VIP Contrafund Initial | 53.7K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Advisor New Insights I | 49.2K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 39.4K | 0.06% | 0.00% | Sep 2026 |
Top institutions holding LTGO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Aberdeen Group PLC | 936K | 1.41% | 0.00% | Sep 2026 |
| Sanofi | 673K | 1.01% | 0.00% | Sep 2026 |
Latigo Biotherapeutics, Inc. Common Stock company profile
- Company name
- Latigo Biotherapeutics, Inc. Common Stock
- Ticker
- LTGO.US
- Exchange
- USA Stocks
- Listed since
- Aug 7, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 66
- Fiscal year end
- December
- Address
- 1300 Rancho Conejo Boulevard, Thousand Oaks, CA, United States, 91320
- Phone
- 805 716 2927
- Website
- latigobio.com
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
Latigo Biotherapeutics, Inc. Common Stock management
10- Ms. Neha KrishnamohanChief Business Officer & CFO · born 1987
- Mr. Nima Farzan M.B.A.Executive Officer · born 1976
- Dr. Neil Kumar Singla M.D.Chief Medical Officer · born 1972
- Mr. Todd N. SmithPresIdent, CEO & Director · born 1970
- Ms. Julia ChapmanSenior Vice President of Operations
- Ms. Caroline DoughertyVice President of Corporate Development
- Mr. Bryan Moyer Ph.D.Senior Vice President of Discovery
- Ms. Polina German Pharm.D.Senior Vice President of Clinical Pharmacology & Translational
- Ms. Sabrina NiederVP & Corporate Controller
- Vicki HollowaySecretary